Novartis reports new Phase III data showing omalizumab significantly improves itch in patients with severe form of chronic skin disease CSU[1]
26 June 2013 | By Novartis
Novartis announced late-breaking results...
List view / Grid view
26 June 2013 | By Novartis
Novartis announced late-breaking results...
24 June 2013 | By Novartis
Sandoz has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel®)...
21 June 2013 | By Novartis
RLX030 has the potential to address a serious unmet medical need...
17 June 2013 | By Novartis
The Novartis Prizes for Immunology are awarded to three scientists...
16 June 2013 | By Novartis
Results from a Phase III three-year follow-up study...
10 June 2013 | By Novartis
Two new analyses from the Phase III TRANSFORMS study presented...
5 June 2013 | By Novartis
Gilenya improved the key measures...
3 June 2013 | By Novartis
Novartis announced data on its investigational compound LDK378...
2 June 2013 | By Novartis
Results from a pivotal Phase III trial...
29 May 2013 | By Novartis
Novartis is joining the global multiple sclerosis community in celebration of World MS Day...
21 May 2013 | By Novartis
New global survey results...
17 May 2013 | By Novartis
Results of a pivotal Phase III trial...
17 May 2013 | By Novartis
"We are proud to be recognized by GBCHealth for our Arogya Parivar program..."
10 May 2013 | By Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab)...
8 May 2013 | By Novartis
"Lucentis was designed to save sight..."